webinar

Characterization and Selection of Antibodies for COVID-19 Diagnostics Using Surface Plasmon Resonance (SPR)

companies Host by: logo   time 02/26/2021, 2PM, EST
  • About the Webinar

    By January 2021, just over a year after the virus was first identified, there were over 100 million cases of COVID-19 reported worldwide and several viral variants in circulation. The unprecedented nature of the pandemic has magnified the need for accelerated scientific discoveries as researchers strive to bring novel therapeutics, vaccines and diagnostic solutions to market.

    One of the core tenets of viral research lies in understanding how the virus interacts with biological targets and protective antibodies, and access to reliable, sensitive and automated technology is paramount to our progress.

    During this session, we'll discuss how surface plasmon resonance (SPR) has been widely adopted for label-free biomolecular characterization, and demonstrate the application of this powerful technique with a study on developing a novel COVID-19 diagnostic assay.

  • You'll Learn About

    Versatility & Flexibility: How the robustness and sensitivity of SPR makes it ideal for a wide range of biomolecular applications

    Comprehensive Workflows: The benefits of SPR-based characterization studies for accelerating lead time on novel COVID-19 solutions

    Maximizing Performance: How to develop a highly selective and specific antibody pair with SPR to optimize COVID-19 antigen detection

    Looking Ahead: The next generation of SPR platforms advancing label-free detection to address the unmet needs of infectious disease research

     

Keynote Speakers

  • Michael Piazza, Ph.D.

    Michael Piazza, Ph.D.
    Systems Integration Manager, Nicoya

    Dr. Mike Piazza is a Systems Integration Manager with proven expertise in improving R&D and decision making in the biotechnology sector. Mike acquired his PhD in chemistry from the University of Waterloo and has years of experience in leveraging SPR platforms to solve researchers' pain points. At Nicoya, Mike identifies, confirms, and interprets performance issues related to individual assays and instrument modules.

  • Soleil Grisé

    Soleil Grisé
    Senior Product Manager, Nicoya

    As Senior Product Manager, Soleil supports the development of innovative surface plasmon resonance (SPR) platforms at Nicoya. Having pursued a BSc from the University of Waterloo and CFA level 1, she combines her interests in the life sciences and finance with her passion for technology adoption to drive innovation in scientific research. By leveraging her diverse background, Soleil is able to bring a comprehensive perspective as she works with leading biotechnology and pharmaceutical organizations to understand their biggest research problems and deliver strategic solutions.

  • Rob Burgess, Ph.D.

    Rob Burgess, Ph.D.
    Chief Business Officer, Sino Biological

    Dr. Burgess has 25 years of experience in the Life Sciences reagents and services industry. After obtaining his doctorate from MD Anderson Cancer Center in 1995 he co-founded the gene targeting and drug discovery company Lexicon Pharmaceuticals, and has since held other positions such as Director of Scientific Sourcing and New Technologies for Serologicals Corporation, Vice President of Business Development for Stem Cell Sciences, Vice President of Business Development for RayBiotech and most recently Chief Business Officer for Sino Biological. In addition, he has published his research in major scientific journals including Nature and Science and has authored two college textbooks focused on the study of stem cells and nanotechnology.

The information and opinions provided by speakers as well as Sino Biological employees during hosted webinar series are solely of their own and Sino Biological assumes no responsibility or liability for this content.

About Sino Biological

Sino Biological specializes in antibody development and recombinant protein production. All of Sino Biological's products are independently developed and produced. Sino Biological offers pharmaceutical companies and biotechnology firms a variety of recombinant production and assay services for pre-clinical research development work. Sino Biological is dedicated to virology and infectious disease research. Its ProVirTM collection is the world's largest viral antigen bank, carrying over 800 products from 350 strains of viruses. Sino Biological is the first company in the world to produce and supply the SARS-CoV-2 viral protein reagents . To support the development of immunodiagnostic assay, Sino Biological has developed a comprehensive collection of antigens and antibodies for SARS-CoV-2.

About Nicoya

Nicoya is a Canadian biotechnology company whose mission is to improve human life by helping scientists succeed. The company develops innovative and accessible SPR platforms for rapid, reliable, and label-free characterization of biomolecules, including antibodies. Nicoya's SPR platforms help biotechnology and pharmaceutical companies bring their latest discoveries to market faster. Currently, Nicoya is empowering 600+ scientists worldwide to push the limits of discovery.